Costs and Benefits of Branded Drugs: Insights from Cost-Effectiveness Research.
- Published in:
- Journal of Benefit-Cost Analysis, 2022, v. 13, n. 2, p. 166, doi. 10.1017/bca.2022.12
- By:
- Publication type:
- Article
Works matching IS 21522812 AND DT 2022 AND VI 13 AND IP 2
Results: 8
1
2
Valuing COVID-19 Morbidity Risk Reductions.
- Published in:
- Journal of Benefit-Cost Analysis, 2022, v. 13, n. 2, p. 247, doi. 10.1017/bca.2022.11
- By:
- Publication type:
- Article
3
BCA volume 13 issue 2 Cover and Back matter.
- Published in:
- Journal of Benefit-Cost Analysis, 2022, v. 13, n. 2, p. b1, doi. 10.1017/bca.2022.8
- Publication type:
- Article
4
The Weak Spot of Infrastructure BCA: Cost Overruns in Seven Road and Railway Construction Projects.
- Published in:
- Journal of Benefit-Cost Analysis, 2022, v. 13, n. 2, p. 224, doi. 10.1017/bca.2022.10
- By:
- Publication type:
- Article
5
BCA volume 13 issue 2 Cover and Front matter.
- Published in:
- Journal of Benefit-Cost Analysis, 2022, v. 13, n. 2, p. f1, doi. 10.1017/bca.2022.7
- Publication type:
- Article
6
The Value of Statistical Life: A Meta-Analysis of Meta-Analyses.
- Published in:
- 2022
- By:
- Publication type:
- Literature Review
7
The Broad Impacts of Disposable Lighter Safety Regulations.
- Published in:
- Journal of Benefit-Cost Analysis, 2022, v. 13, n. 2, p. 149, doi. 10.1017/bca.2022.6
- By:
- Publication type:
- Article
8
Dynamic Versus Static Modeling of Mortality-Related Benefits of PM2.5 Reductions in the USA and Chile: 1990 to 2050.
- Published in:
- Journal of Benefit-Cost Analysis, 2022, v. 13, n. 2, p. 198, doi. 10.1017/bca.2022.5
- By:
- Publication type:
- Article